Table 4.
Efficacy comparison of entecavir and lamivudine for continuous outcomes.
| Outcome of interest | Number of studies | Sample size | Effect estimate | Heterogeneity | |||
|---|---|---|---|---|---|---|---|
| Entecavir | Lamivudine | MD (95% CI) | p value | I 2 (%) | p value | ||
| TBIL level | |||||||
| 1 month | 3 | 134 | 126 | −12.43 (−36.43, 11.58) | 0.31 | 0 | 0.42 |
| 3 months | 3 | 236 | 229 | −1.69 (−6.66, 3.29) | 0.51 | 0 | 0.82 |
| 12 months | 3 | 215 | 201 | −8.73 (−12.74, −4.72) | <0.0001 | 0 | 0.73 |
| ALT level | |||||||
| 1 month | 4 | 303 | 286 | −4.96 (−10.07, 0.14) | 0.06 | 0 | 0.64 |
| 12 months | 3 | 215 | 201 | −3.08 (−6.08, −0.07) | 0.04 | 0 | 0.68 |
| PTA level | |||||||
| 1 month | 4 | 283 | 274 | 2.12 (0.42, 3.82) | 0.01 | 21% | 0.29 |
| 3 months | 3 | 236 | 229 | 1.91 (−1.33, 5.15) | 0.25 | 0 | 0.76 |
| 12 months | 3 | 215 | 201 | 3.6 (−1.07, 8.26) | 0.13 | 0 | 0.99 |
TBIL: total bilirubin; ALT: alanine aminotransferase; PTA: prothrombin activity; MD: mean difference; CI: confidence interval.